News | Cardio-oncology | January 03, 2019

Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab

Study finds heart drug carvedilol reduces major cardiac side effects of breast cancer treatment

Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab

January 3, 2019 — Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented recently at EuroEcho-Imaging 2018, Dec. 5-8 in Milan, Italy.1

“Heart damage is a major side effect of the breast cancer drug trastuzumab and may force patients to stop treatment,” said lead author Maryam Moshkani Farahani, M.D., associate professor, Baqiyatallah University of Medical Sciences, Tehran, Iran. “Our study suggests that patients who take the beta-blocker carvedilol together with trastuzumab have less heart damage than those who take trastuzumab alone.”

The study enrolled 71 patients with non-metastatic HER2-positive breast cancer. Patients were randomly allocated to receive trastuzumab with, or without, carvedilol.

Impaired function of the heart’s left ventricle is the main type of heart damage caused by trastuzumab. Carvedilol is used to treat patients with impaired left ventricular function after a heart attack. It is also prescribed for heart failure and high blood pressure.

For the study, an imaging technique called two-dimensional speckle tracking echocardiography was used to assess the systolic and diastolic function of the left ventricle initially and at three months. Specifically, systolic function was measured using global longitudinal strain and strain rate, while diastolic function was assessed with strain rate.

According to all of the measurements, systolic and diastolic left ventricular function were better preserved at three months in patients who took carvedilol with trastuzumab compared to those who took trastuzumab alone.

The pumping function of the heart (left ventricular ejection fraction) did not differ between treatment groups at the start of the study or at three months. “The measures we used to assess left ventricular function – namely global longitudinal strain and strain rate – are more sensitive than left ventricular ejection fraction,” explained Moshkani Farahani.

She noted that carvedilol can cause side effects, such as dizziness, drowsiness, fainting, mood changes, shortness of breath and diarrhoea. Patients who feel unwell when taking the medication should consult their doctor.

Moshkani Farahani concluded: “The findings indicate that carvedilol may be an effective way to prevent the heart damage caused by trastuzumab treatment. We now advise our patients with non-metastatic HER2-positive breast cancer to take prophylactic carvedilol, but a larger study is needed before firm recommendations can be made.”

For more information: www.escardio.org

 

Reference

1. Moshkani Farahani M., Nourian S. Assessment of treatment with Carvedilol in preventing early stage left ventricular dysfunction in breast cancer patients by 2D speckle tracking echocardiography. Presented at EuroEcho-Imaging, Dec. 5, 2018.

Related Content

New Multimodality Cardiac Imaging Guidelines for Competitive Athletes Created. ASE SCCT and SCMR recommendations for imaging, screening atheletes.
News | Cardiac Imaging | May 11, 2020
May 11, 2020 – Competitive athletes are a rapidly growing population worldwide.
Figure 4 for the study. Images of a 65-year-old man (patient 6). (a) Cardiac MRI perfusion shows perfusion deficit of anterior/anterolateral wall attributed to left anterior descending artery/left circumflex artery (*). (b) CT coronary angiography. (c) Coronary angiography, left anterior oblique projection with caudal angulation. (d) Three-dimensional image fusion helped refine diagnosis: perfusion deficits (*) were most likely caused by narrow first diagonal branch and its first, stented side branch (arrow

Figure 4 for the study. Images of a 65-year-old man (patient 6). (a) Cardiac MRI perfusion shows perfusion deficit of anterior/anterolateral wall attributed to left anterior descending artery/left circumflex artery (*). (b) CT coronary angiography. (c) Coronary angiography, left anterior oblique projection with caudal angulation. (d) Three-dimensional image fusion helped refine diagnosis: perfusion deficits (*) were most likely caused by narrow first diagonal branch and its first, stented side branch (arrowhead). Retrospectively, denoted lesion could also be found at CT coronary angiography and coronary angiography (arrowheads in b and c, respectively). CT FFR = CT-derived fractional flow reserve, LGE = late gadolinium enhancement. Image courtesy of RSNA, Radiology.

News | Cardiac Imaging | May 04, 2020
May 4, 2020 – A new technique that combines computed tomography (CT) and magnetic resonance imaging MRI can bolster c
An example of a coronary computed tomography angiography (CCTA) exam. The CIAO study looked at patients who have a problem of blood flow limitation and chest pain symptoms in the absence of a 50 percent or more artery narrowing, known as ischemia with no obstructive CAD, or INOCA.

An example of a coronary computed tomography angiography (CCTA) exam. The CIAO study looked at patients who have a problem of blood flow limitation and chest pain symptoms in the absence of a 50 percent or more artery narrowing, known as ischemia with no obstructive CAD, or INOCA.

News | Cardiac Imaging | April 03, 2020
April 3, 2020 — Patients who experience chest pain and have abnormal results on a cardiac stress test but who do not
Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data

Figure 1: Depiction of the fully automated CT biomarkers tools used in this study. (A) Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data. (B) Case example in an asymptomatic 52-year-old man undergoing CT for colorectal cancer screening. At the time of CT screening, he had a body-mass index of 27·3 and Framingham risk score of 5% (low risk). However, several CT-based metabolic markers were indicative of underlying disease. Multivariate Cox model prediction based on these three CT-based results put the risk of cardiovascular event at 19% within 2 years, at 40% within 5 years, and at 67% within 10 years, and the risk of death at 4% within 2 years, 11% within 5 years, and 27% within 10 years. At longitudinal clinical follow-up, the patient suffered an acute myocardial infarction 3 years after this initial CT and died 12 years after CT at the age of 64 years. (C) Contrast-enhanced CT performed 7 months before death for minor trauma was interpreted as negative but does show significant progression of vascular calcification, visceral fat, and hepatic steatosis. HU=Hounsfield units.

News | Cardiac Imaging | March 06, 2020
March 6, 2020 — Researchers at the National Institutes of Health a
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along with eight other...
Philips Debuts Cardiac Ultrasound and Enterprise Informatics Offerings at ESC 2019
News | Cardiac Imaging | August 30, 2019
Philips will showcase its latest cardiac care innovations at the European Society of Cardiology (ESC) Congress 2019,...